NASDAQ:UROV

Urovant Sciences Competitors

$16.24
0.00 (0.00 %)
(As of 03/29/2021)
Add
Compare
Today's Range
$16.24
Now: $16.24
$16.24
50-Day Range
$16.17
MA: $16.21
$16.24
52-Week Range
$7.15
Now: $16.24
$16.26
VolumeN/A
Average Volume114,469 shs
Market Capitalization$531.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Competitors

Urovant Sciences (NASDAQ:UROV) Vs. IGMS, RVNC, DRNA, AXSM, NGM, and MORF

Should you be buying UROV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Urovant Sciences, including IGM Biosciences (IGMS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), and Morphic (MORF).

IGM Biosciences (NASDAQ:IGMS) and Urovant Sciences (NASDAQ:UROV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares IGM Biosciences and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.45

IGM Biosciences is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IGM Biosciences and Urovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
Urovant SciencesN/AN/A-162.90%

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for IGM Biosciences and Urovant Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
Urovant Sciences03002.00

IGM Biosciences currently has a consensus target price of $98.8750, suggesting a potential upside of 44.36%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given IGM Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Urovant Sciences.

Summary

IGM Biosciences beats Urovant Sciences on 7 of the 11 factors compared between the two stocks.

Revance Therapeutics (NASDAQ:RVNC) and Urovant Sciences (NASDAQ:UROV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares Revance Therapeutics and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.45

Urovant Sciences has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Revance Therapeutics and Urovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
Urovant SciencesN/AN/A-162.90%

Institutional & Insider Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Revance Therapeutics and Urovant Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics00503.00
Urovant Sciences03002.00

Revance Therapeutics currently has a consensus target price of $36.40, suggesting a potential upside of 29.40%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given Revance Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Urovant Sciences.

Summary

Revance Therapeutics beats Urovant Sciences on 8 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.45

Dicerna Pharmaceuticals has higher revenue and earnings than Urovant Sciences. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dicerna Pharmaceuticals and Urovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Urovant SciencesN/AN/A-162.90%

Institutional & Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Dicerna Pharmaceuticals and Urovant Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
Urovant Sciences03002.00

Dicerna Pharmaceuticals currently has a consensus target price of $37.8333, suggesting a potential upside of 45.01%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than Urovant Sciences.

Summary

Dicerna Pharmaceuticals beats Urovant Sciences on 9 of the 13 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Institutional & Insider Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Axsome Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Profitability

This table compares Axsome Therapeutics and Urovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Urovant SciencesN/AN/A-162.90%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Axsome Therapeutics and Urovant Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Urovant Sciences03002.00

Axsome Therapeutics currently has a consensus target price of $146.90, suggesting a potential upside of 177.22%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Urovant Sciences.

Earnings and Valuation

This table compares Axsome Therapeutics and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.45

Axsome Therapeutics is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Axsome Therapeutics beats Urovant Sciences on 9 of the 11 factors compared between the two stocks.

Urovant Sciences (NASDAQ:UROV) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

18.4% of Urovant Sciences shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 2.7% of Urovant Sciences shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Urovant Sciences has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Urovant Sciences and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Urovant SciencesN/AN/A-162.90%
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Analyst Recommendations

This is a breakdown of current recommendations for Urovant Sciences and NGM Biopharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urovant Sciences03002.00
NGM Biopharmaceuticals00523.29

Urovant Sciences presently has a consensus price target of $16.1667, suggesting a potential downside of 0.45%. NGM Biopharmaceuticals has a consensus price target of $39.1111, suggesting a potential upside of 53.80%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NGM Biopharmaceuticals is more favorable than Urovant Sciences.

Earnings & Valuation

This table compares Urovant Sciences and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.45
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92

NGM Biopharmaceuticals has higher revenue and earnings than Urovant Sciences. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats Urovant Sciences on 10 of the 14 factors compared between the two stocks.

Urovant Sciences (NASDAQ:UROV) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

18.4% of Urovant Sciences shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 2.7% of Urovant Sciences shares are owned by insiders. Comparatively, 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Urovant Sciences has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares Urovant Sciences and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Urovant SciencesN/AN/A-162.90%
MorphicN/A-36.62%-20.69%

Analyst Recommendations

This is a breakdown of current recommendations for Urovant Sciences and Morphic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urovant Sciences03002.00
Morphic00203.00

Urovant Sciences presently has a consensus price target of $16.1667, suggesting a potential downside of 0.45%. Morphic has a consensus price target of $63.3333, suggesting a potential upside of 6.71%. Given Morphic's stronger consensus rating and higher probable upside, analysts plainly believe Morphic is more favorable than Urovant Sciences.

Earnings & Valuation

This table compares Urovant Sciences and Morphic's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.45
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06

Morphic has higher revenue and earnings than Urovant Sciences. Morphic is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Morphic beats Urovant Sciences on 9 of the 12 factors compared between the two stocks.


Urovant Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49flat$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13flat$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09flat$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99flat$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43flat$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35flat$1.93 billion$16.98 million-38.04Insider Selling
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57flat$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58flat$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02flat$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16flat$1.87 billion$64.19 million-9.96
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96flat$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05flat$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94flat$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93flat$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16flat$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57flat$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57flat$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99flat$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15flat$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26flat$1.64 billionN/A0.00Insider Selling
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19flat$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80flat$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32flat$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61flat$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41flat$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20flat$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28flat$1.53 billionN/A0.00Lockup Expiration
uniQure logo
QURE
uniQure
1.7$33.74flat$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60flat$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56flat$1.51 billion$82.27 million-18.44Unusual Options Activity
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96flat$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88flat$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31flat$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30flat$1.49 billionN/A0.00Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19flat$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00flat$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20flat$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80flat$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16flat$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95flat$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62flat$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84flat$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80flat$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35flat$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51flat$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90flat$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69flat$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49flat$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70flat$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39flat$1.18 billion$59.70 million-193.90Unusual Options Activity
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.